Group | CD3+(%) | CD3+CD4+(%) | CD3+CD8+(%) | CD4+/CD8+ | CD3−CD56+(%) | IL-2 (ng/L) | IFN-r (pg/mL) |
---|---|---|---|---|---|---|---|
Treatment group | Â | Â | Â | Â | Â | Â | Â |
 Pre-treatment | 62.16 ± 13.62 | 33.64 ± 10.05 | 25.86 ± 10.30 | 1.55 ± 0.88 | 17.83 ± 9.04 | 330.42 ± 79.25 | 575.85 ± 179.85 |
 Post-treatment | 66.34 ± 13.65 | 34.63 ± 13.28 | 29.73 ± 11.14 | 1.45 ± 0.97 | 17.31 ± 9.50 | 330.94 ± 66.12 | 567.12 ± 151.64 |
 P value | 0.3 | 0.716 | 0.119 | 0.684 | 0.806 | 0.979 | 0.831 |
Control group | Â | Â | Â | Â | Â | Â | Â |
 Pre-treatment | 68.70 ± 15.48 | 39.48 ± 12.76 | 27.30 ± 8.79 | 1.57 ± 0.67 | 10.25 ± 6.12 | 358.37 ± 49.00 | 491.19 ± 60.00 |
 Post-treatment | 70.43 ± 19.67 | 33.6471 ± 18.02 | 33.65 ± 17.19 | 1.27 ± 0.96 | 8.52 ± 6.52 | 376.09 ± 44.44 | 507.32 ± 59.87 |
 P value | 0.705 | 0.051 | 0.077 | 0.08 | 0.378 | 0.186 | 0.481 |